strategic application of pbpk models for predicting ddis & the effects of smoking & organ impairment
Published 2 years ago • 566 plays • Length 59:17Download video MP4
Download video MP3
Similar videos
-
50:40
application of pbpk modeling in predicting p-glycoprotein-mediated drug-drug interactions
-
55:39
a best practice framework for applying pbpk modeling to pediatric drug development
-
1:01:26
iq wg evaluation of pbpk models for organ-impaired populations
-
59:17
applications of pbpk modelling for regulatory submissions: case studies
-
49:40
pbpk modeling and simulation: bridging the “bottom up” and “top-down” approaches
-
40:57
precision dosing using pbpk modeling
-
1:05:52
application of physiologically-based pharmacokinetics (pbpk) to personalized dosing
-
50:49
pbpk modeling and simulation for regulatory decision making: impact on us prescribing information
-
1:52
pbpk modeling supports approval of breakthrough cancer drug
-
58:36
pbpk for the pill an approach to assess the risk benefit of drugs
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
1:13:05
pbpk modelling to predict salt form advantage when dosed with acid-reducing agents
-
1:02:16
leveraging dermal pbpk modeling and simulation approaches
-
55:43
pbpk modelling to predict drug-biologic interactions with cytokine modulators
-
51:29
what’s new in the simcyp simulator v18
-
1:01:14
pbpk modeling & simulation to support asciminib nda submission and inform drug product label
-
36:08
pbpk modeling of antibody-drug conjugates – concept and application
-
38:36
getting at the haart of precision dosing: using pbpk models to optimize dosing of an antiviral